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Abstract 
 
Background 
 Anticoagulation with oral vitamin K antagonists (VKA) is very important in 
patients supported on a left ventricular assist device (LVAD) to prevent 
thromboembolic complications. Some patients tolerate VKAs poorly and have an 
unstable INR as a result. It is reported that low-dose vitamin K can improve INR 
control in patients with an unstable INR in other clinical settings. We evaluated its 
safety and effectiveness in patients on LVAD support. 
Methods 
The records of all patients supported on an implantable LVAD between January, 
2013 and March, 2014 were reviewed retrospectively to identify those who had 
received low-dose vitamin K while on warfarin. INR values and warfarin doses 
before and after initiation of vitamin K supplementation were compared to 
evaluate its effectiveness. 
Results 
There were six LVAD patients who were on low-dose vitamin K due to an 
unstable INR out of a total of 59 VAD patients followed as an outpatient. The 
standard deviation (SD) of INR decreased significantly after starting vitamin K 
(p=0.04) while the SD of warfarin dose did not (p=0.22). Comparing divergence 
from target INR, INR became significantly closer to target INR after starting 
vitamin K. The number of bleeding complications tended to be fewer on vitamin 
K, but this did not reach statistical significance (p=0.09). 
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Conclusions 
Daily low-dose vitamin K supplementation can improve INR control in LVAD 
patients with unstable INR without increasing thromboembolic complications. 
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Introduction 
Appropriate anticoagulation is important in the management of patients on left 
ventricular assisting device (LVAD) support.1 A stable level of anticoagulation is 
desired to minimize anticoagulation-related morbidity.2, 3 However, the degree of 
anticoagulation produced by vitamin K antagonists, such as warfarin, depends on 
various factors.4 Maintaining an appropriate international normalization ratio 
(INR) often requires frequent blood tests and changes in the warfarin dosage. 
One cause of INR instability is insufficient daily vitamin K intake.5 There are 
several reports of achieving a stable INR by adding low-dose vitamin K in 
patients with an unstable INR in those who have atrial fibrillation or other 
common needs for anticoagulation. 5 However, data on low-dose vitamin K in 
LVAD patients are lacking. Therefore, we evaluated the effectiveness of low-
dose vitamin K to achieve stability in LVAD patients with an unstable INR. 
Methods 
The records for all patients on long-term support with a continuous flow LVAD 
and followed at Thomas Jefferson University Hospital between January 1, 2013 
and March 31, 2014 were reviewed to identify those patients who were being 
treated with low-dose oral vitamin K due to an unstable INR. There were no 
specific criteria for the definition of an unstable INR. Vitamin K initiation was at 
the discretion of the treating physicians. Vitamin K tablets (100 mcg) were 
obtained by the patients as a dietary supplement at retail stores. Data on the INR 
and warfarin dosing were collected up to three months before and after initiation 
of vitamin K supplementation, reviewing patient charts retrospectively. When 
vitamin K was started during the implant hospital admission, data during the 
admission were used in addition to outpatient data to complete the three-month 
follow-up. When vitamin K was started during outpatient follow up, outpatient 
data were used. In order to compare the degree of INR control before and after 
initiation of vitamin K supplementation, three factors were evaluated statistically. 
Firstly, the variance of INR and warfarin doses was compared using F-test, since 
significantly smaller variance would suggest better control. Secondly, differences 
between measured INR and median of target INR range (divergence) were 
compared using Student’s t-test. Smaller divergence indicates INR closer to 
target, proving better INR control. Lastly, average INR and warfarin doses were 
also compared to evaluate impact of vitamin K on actual INR values and warfarin 
dosage. The INR goal range was individualized for each patient and was based 
on clinical risk factors for thrombosis or hemorrhage, as well as prior thrombotic 
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or bleeding events. Complications from anticoagulation including bleeding and 
thromboembolic event were also evaluated. 
Results 
There were six LVAD patients who were on low-dose vitamin K due to an 
unstable INR out of a total of 59 VAD patients followed as an outpatient. In 
general, the patients had a labile INR, with values well above the therapeutic 
range on minimal warfarin, or fluctuating between supra-therapeutic and sub-
therapeutic despite changes in warfarin dosing. Table 1 shows INR and warfarin 
doses of each patient before and after the initiation of vitamin K. The variance of 
INR was significantly smaller in five of six cases (83%) after initiation of vitamin 
K. The average INR decreased significantly in two of six cases (33%).  
Differences between measured INR and median of target INR range (divergence) 
were significantly better in three of six cases (50%) after initiation of vitamin K. 
The average warfarin dose decreased significantly in one case but was not 
significantly different in other cases. In three of the patients, the average INR was 
below the lower end of the individualized target range after initiation of vitamin K, 
but the range of INR values obtained were narrower, corresponding to the 
improved divergence seen.  
Table 2 shows averages of six patients and comparison of each before and after 
initiation of vitamin K. Average number of complications during follow up periods 
is also shown. The SD of INR decreased significantly after initiation of vitamin K 
(p=0.04) while the SD of warfarin doses did not (p=0.22). Comparing divergence 
of unstable patients before and after vitamin K, INR became significantly closer 
to target INR after initiation of vitamin K. None of the patients had 
thromboembolic complications after being started on vitamin K, even though INR 
tended to be lower. The number of bleeding complications tended to be fewer on 
vitamin K, but this was not statistically significant (p=0.09). 
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Table 1: Changes in warfarin control before and after initiation of vitamin K 
supplementation. 
Case  No vitamin K Vitamin K 
Variance 
(F-test) 
Difference 
(t-test) 
1 
INR 
(target 1.8-2.0) 
2.41±1.23 
(1.2-5.3) 
2.94±1.34 
(1.2-4.8) 
NS NS 
Warfarin (mg) 3.61±0.91 3.54±1.69 <0.05 NS 
divergence 0.88±1.00 1.23±1.16  NS 
2 
INR  
(target 1.8-2.0) 
1.81±067 
(1.1-3.5) 
1.55±0.20 
(1.3-1.8) 
<0.001 NS 
Warfarin (mg) 5.58±1.36 3.84±1.32 NS <0.01 
divergence 0.57±0.33 0.35±0.20  <0.05 
3 
INR 
(target 1.8-2.5) 
2.54±0.80 
(1.7-3.88) 
1.92±0.43 
(1.5-2.91) 
<0.05 <0.05 
Warfarin (mg) 1.06±0.40 1.15±0.32 NS NS 
divergence 0.63±0.63 0.44±0.21  NS 
4 
INR 
(target 1.5-1.8) 
3.30±0.93 
(1.3-4.36) 
1.73±0.29 
(1.3-2.57) 
<0.001 <0.01 
Warfarin (mg) 3.56±2.25 4.56±0.37 <0.001 NS 
divergence 1.50±0.80 0.22±0.20  <0.01 
5 
INR 
(target 2.0-2.5) 
2.27±1.18 
(1.13-5.09) 
1.74±0.50 
(1.32-2.87) 
<0.05 NS 
Warfarin (mg) 1.65±1.32 2.00±0.47 <0.01 NS 
divergence 0.98±0.67 0.57±0.19  <0.05 
6 
INR  
(target 2.0-2.2) 
2.14±1.22 
(1.28-3.61) 
1.91±0.54 
(1.43-3.44) 
<0.001 NS 
Warfarin (mg) 0.94±1.04 0.81±0.40 <0.001 NS 
divergence 0.94±0.77 0.49±0.30  NS 
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Continuous data are expressed as mean ± standard deviation. Target range and 
highest and lowest values are shown for INR. Divergence is the difference 
between measured INR and median of target INR. 
 
Table 2.  Comparison of averages of 6 patients before and after initiation of 
vitamin K supplementation.  
 
Continuous data are expressed as mean ± standard deviation. Data of bleeding 
and thromboembolic complications are number of events during follow-up 
periods. 
Discussion 
These results all indicate significantly better INR control after initiation of vitamin 
K supplementation, which can theoretically lead to fewer complications from INR 
out of therapeutic range. Furthermore, the absence of thromboembolic 
complication after starting low-dose vitamin K suggests safety of its use even in 
patients on an LVAD. The target range for INR in our patients has fluctuated with 
time as more data on the risk of pump thrombosis have become available. In 
addition, our target range varies between patients based on clinical criteria. 
Patients who have had numerous bleeding episodes will usually be assigned a 
low INR range, while a higher range will be used in those with heparin induced 
thrombocytopenia, atrial fibrillation, documented or suspected hypercoagulable 
state, or thromboembolic episodes. Despite the fact that half of our patients had 
an average INR below the lower limit of their target range, there was less 
divergence between their actual INR and target INR after initiation of vitamin K 
supplementation, suggesting better overall control. In addition, there were no 
thromboembolic events in any patients during the three-month follow-up period or 
since thereafter. Another advantage is that low-dose vitamin K therapy is 
 No vitamin K Vitamin K p 
INR 
Mean 2.41±0.46 1.96±0.45 NS 
SD 1.00±0.22 0.55±0.37 <0.05 
divergence 0.86±0.78 0.56±0.63 <0.01 
Warfarin (mg) 
Mean 2.73±1.67 2.65±1.41 NS 
SD 1.21±0.56 0.76±0.54 NS 
Bleeding 0.83±0.69 0.17±0.37 0.09 
Thromboembolic 0 0 - 
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affordable and available over-the-counter, hence it can even be cost-beneficial 
by reducing complications and frequency of INR tests. The major limitations of 
this study are its retrospective design and relatively small number of cases. A 
prospective randomized case-control study with a larger case volume would be 
necessary to further validate the effectiveness of vitamin K in patients on LVAD 
support. 
In conclusion, daily low-dose vitamin K supplementations potentially improve INR 
control in LVAD patients with unstable INR without increasing the 
thromboembolic complications.  
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